BOTHELL, Wash., Aug. 21 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics today announced that the company will be presenting an update on NWBT’s lead product candidate, DCVax(R)-Brain for Glioblastoma multiforme (GBM), at the Cambridge Healthtech Institute’s (CHI) 3rd Annual Cancer Immunotherapeutics and Vaccines Conference, August 22nd-23rd at the Royal Sonesta Hotel in Cambridge, Massachusetts. Company President Alton Boynton, Ph.D., will give an oral presentation during the Dendritic Cells session at the CHI conference at 10:45 AM EDT, Wednesday, August 23rd. Dr. Boynton will describe the Phase I survival and progression data on patients who have received DCVax(R)-Brain, a therapeutic personalized cancer vaccine. Dr. Boynton will be available to discuss the findings and the planned commercial development of DCVax(R)-Brain as a highly promising new cancer therapy for most cancers.
The Company’s two Phase I clinical trials of DCVax(R)-Brain involved patients with GBM, the most lethal form of brain cancer. Dendritic cell-based immunotherapy, such as NWBT’s DCVax(R)-Brain vaccine, uses autologous dendritic cells that are pulsed with tumor biomarkers (antigens). This therapeutic approach aims at safely stimulating anti-tumor immune responses to prevent tumor recurrence or progression.
The two Phase I clinical trials were carried out at University of California, Los Angeles (UCLA) under the direction of Linda Liau, M.D., Ph.D., Associate Professor of Neurosurgery and Director of the Malignant Brain Tumor Program at the UCLA School of Medicine. Dr. Liau will serve as Principal Investigator for the upcoming Phase II trial.
Details about the ongoing, long-term survival data from the second Phase I trial will be presented.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company’s three lead product candidates are: DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; and CXCR4 a therapeutic monoclonal antibody for treatment of solid tumors, that is in late preclinical development.
Statements made in this press release that are not historical facts are forward-looking statements including, without limitation, the statements regarding completion of the private placement and the anticipated gross proceeds of the private placement and the uses thereof. These forward-looking statements are subject to risks and uncertainties that could cause actual events to differ materially from those stated including, among others, risks related to the satisfaction or waiver of the conditions to closing the private placement and the risk that the private placement may not be consummated, as well as those risks and uncertainties disclosed from time to time in reports filed by the Company with the U.S. Securities and Exchange Commission. Additional information on factors, which could affect the Company’s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Northwest Biotherapeutics
CONTACT: Lorie Calvo of Northwest Biotherapeutics, +1-425-608-3008
Web site: http://www.nwbio.com/
